- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04575350
Reinterpretation of CNV With Unknown Significance: a 5-year Retrospective Analysis (ReAC)
Intérêt de la réinterprétation Des CNV de Signification Inconnue Mis en évidence Par ACPA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Array-CGH is a front-line technique in many genetic indications in both prenatal and postnatal settings. It allows the detection of chromosomal rearrangements (duplication or deletion for example) in routine. The interpretation and classification of these copy number variations or CNVs is essential but complex. It requires a systematic and methodical analysis of the variation in the context of the scientific literature. When these revisions do not meet either pathogenicity or benignity criteria, they are referred to as variation of unknown significance (or VUS). They account for a significant proportion of the revisions up to 75% (Palmer et al., 2013).
The detection of VUS does not, in most cases, allow for a diagnosis and often requires the use of other, costly techniques. The human impact may also be significant in the absence of possible genetic counselling (e.g. in the context of a future pregnancy). Reanalysis of an VUS is of major interest for at least two reasons : (1) the first, if it is classified as benign, makes it possible to close the investigation of the variant, to consider other leads without ulterior motives, and to reassure the patient about the absence of pathogenicity of the variant. (2) if the VUS is ultimately pathogenic, this makes it possible to name the disease for the patient, to specify genetic counselling, to avoid further long and costly investigation and possibly to propose treatment.
Currently, VUS can be reanalysed by the laboratory at the request of the prescribing physician or possibly another physician. However, no systematic reanalysis procedure is currently in place.
Although these variations of unknown meanings are frequent and represent an important issue, to our knowledge, no systematic database study has been carried out. Some similar work has nevertheless been carried out over a shorter period or on an ad hoc basis, showing an interest in this type of approach (Palmer et al., 2014).
Indeed, it seems essential to determine the interest of reanalysing such variations in several modes: diagnostic, economic and human.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nancy, France
- Lorraine University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed consent for array-CGH (authorization for the conservation of a biological sample and its subsequent use to continue investigations);
- array-CGHcarried out at the genetics laboratory in Nancy between 1st January 2010 and 31th December 2017 (considering the date of validation of the report);
- Identification of variations of unknown clinical significance.
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort
no intervention.
|
Reinterpretation of CNV of unknown significance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Define the overall rate and per year of reclassification of CNVs after systematic analysis of all those identified as VUS between 2010 and 2016.
Time Frame: between july 2019 and november 2019
|
The proportion of pathogenic variants will correspond to the percentage of pathogenic variants among all reclassified variants.
|
between july 2019 and november 2019
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Among the reclassified CNVs, define the proportion of pathogenic variants ;
Time Frame: between july 2019 and november 2019
|
The proportion of pathogenic variants will correspond to the percentage of pathogenic variants among all reclassified variants.
|
between july 2019 and november 2019
|
Among the CNVs reclassified as pathogens, define the proportion of new diagnoses ;
Time Frame: between july 2019 and november 2019
|
The proportion of new diagnoses corresponds to the proportion of patients for whom the pathogenicity is related to the pathology among all resolved pathogenic variants.
|
between july 2019 and november 2019
|
Compare the rate of reclassification of CNVs by type (deletion/duplication)
Time Frame: between july 2019 and november 2019
|
The type of reclassification is defined either by deletion or by chromosomal duplication
|
between july 2019 and november 2019
|
Compare the size of the CNV according to the type of reclassification of the variant.
Time Frame: between july 2019 and november 2019
|
in bp
|
between july 2019 and november 2019
|
Compare the reclassification rate by type of disease.
Time Frame: between july 2019 and november 2019
|
The following types of conditions will be considered: prenatal/postnatal; intellectual disability or neurodevelopmental disorder/malformation/other.
|
between july 2019 and november 2019
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lambert Laëtitia, MD, PhD, CHRU Nancy, Lorraine University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ReAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Disease
-
Boston Children's HospitalNational Human Genome Research Institute (NHGRI)Active, not recruitingGenetic Disease | Genetic PredispositionUnited States
-
Boston Children's HospitalRecruitingGenetic Predisposition to Disease | Genetic Disease | Development, Infant | Genetic Syndrome | Development, ChildUnited States
-
National Cancer Institute (NCI)Active, not recruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
University of WashingtonNational Cancer Institute (NCI)Completed
-
Anahuac UniversityCompletedGenetic Predisposition | Carrier, GestationalMexico
-
University Hospital TuebingenCharite University, Berlin, Germany; RWTH Aachen University; Medical University...Not yet recruiting
-
King Hussein Cancer CenterActive, not recruiting
-
University of Texas Southwestern Medical CenterNational Society of Genetic CounselorsCompletedGenetic PredispositionUnited States
-
National Cancer Institute (NCI)RecruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
St. Jude Children's Research HospitalRecruitingGenetic PredispositionUnited States
Clinical Trials on reinterpretation of CNV
-
Chen Zi-JiangChinese Academy of SciencesCompleted
-
University of GaziantepCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; Southwest Hospital, China; West... and other collaboratorsActive, not recruiting
-
Qilu Hospital of Shandong UniversityRecruitingProstate CarcinomaChina
-
Changhai HospitalRenJi Hospital; West China Hospital; Tongji Hospital; Qilu Hospital of Shandong... and other collaboratorsRecruitingUrothelial CarcinomaChina
-
Bryan DennyNational Institute on Aging (NIA)RecruitingStress | Emotions | Emotion Regulation | Psychological | Caregivers | PsychophysiologyUnited States
-
Regeneron PharmaceuticalsCompletedSystemic Juvenile Idiopathic ArthritisUnited States
-
Cryonove PharmaCEISO; Dermatech; INNOVSOLUTIONCompleted
-
Charles University, Czech RepublicUniversity Hospital Hradec KraloveUnknownPrimary AldosteronismCzech Republic
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedProstate CancerUnited States, Canada, Puerto Rico